KRAS and pancreatic neoplasm: Of note, the notion that KRAS mutations operate independently of upstream signaling has been challenged by genetic mouse models of lung and pancreatic cancers, which showed that EGFR inhibition prevented the growth of KRAS-mutated tumors.